Material and method In this retrospective study, rate of abnormalities of TFT, its association with morbidities and neurodevelopment is investigated in 139 premature babies admitted to neonatal intensive care unit in Uludag University Medical Faculty between January 2009 and January 2012.

Results Mean gestational weeks and birth weights of infants were 31.3 ± 2.9 weeks 1667 ± 707 gr. Forty one patients (24%) had TFT abnormality, 53.6% had transient TSH elevation, 22% had primary hypothyroidism, 22% had non-thyroidal disease and 2.4% had transient hypothyroxinemia. Forty seven percent of SGA babies and, 26% of AGA babies had TFT abnormalities, difference was not statistically significant. Most common TFT abnormality was found to be transient TSH elevation in SGA and AGA babies. Mothers of 8 patients had maternal hypothyroidism. Five of these babies (63.5%) had TFT abnormality ($p = 0.049$). Mean head circumference in 18 months of age in normal TFT group was $46.3 \text{ cm} \pm 1.6$ compared to babies with abnormal TFT whose mean head circumference was $45 \text{ cm} \pm 2.4$ at the same age, difference was statistically significant. There were no statistically significant difference between groups for antropometric values in 6, 9, 12 months and neurodevelopmental evaluation.

Conclusion TFT abnormalities are frequent in premature babies and it is one of the most common causes of preventable mental retardation. In neonates, even transient hypothyroidism is associated with poor neurodevelopmental outcome, hence it must be treated urgently. As also detected in our study, maternal hypothyroidism is associated with increased neonatal hypothyroidism and these babies must be managed closely in postnatal period. Although not statistically significant, SGA babies were found to have increased rate of hypothyroidism. Further investigation with larger number of patients is necessary.

PS-042c IS LOW-DOSE COMBINED ORAL CONTRACEPTIVES USE ASSOCIATED TO LOWER BONE MINERAL CONTENT VARIATION IN ADOLESCENTS OVER A ONE-YEAR PERIOD?

¹TB Goldberg, ¹TP Bion, ²CS Kurokawa, ²MR Moretto, ³AS Teixeira, ⁴HRC Nunes. ¹Department of Pediatrics – Adolescent Medicine Course – Graduate Program in Gynecology Obstetrics and Mastology, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil; ²Clinical and Experimental Pediatrics Research Center – Department of Pediatrics, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil; ³Department of Tropical Diseases and Diagnostic Imaging, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil; ⁴Statistical Consultant, Botucatu School of Medicine – São Paulo State University (UNESP), Botucatu, Brazil

10.1136/archdischild-2014-307384.339

Background Low dose combined oral contraceptives (COC) can interfere in bone mass acquisition during adolescence. To evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose (EE 20 µg/Desogestrel 150 µg) combination oral contraceptive (COC) over a one-year period and compare with healthy adolescents from the same age group not taking COCs.

Methods A non-randomised parallel control study with one-year follow-up. Sixty-seven adolescents from 12 to 20 years of age, divided into COC users ($n = 41$) taking 20 µg EE/150 µg Desogestrel and non-user controls ($n = 26$), were evaluated through bone densitometry examinations at baseline and 12 months later. Comparisons between groups at study start was done through the Mann-Whitney test with significance level fixed at 5% or

corresponding p value; comparisons between groups at study start and 12 months later used variations in median percentages for bone mass variables.

Results COC users presented low bone mass acquisition in the lumbar spine and BMD and BMC median variations between baseline and at 12 months of 2.07% and +1.57% respectively whereas the control group presented variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC presented similar evolution during the study in both groups. Statistical significance (p) **Conclusion** The use of a low COC dose (EE 20 µg/Desogestrel 150 µg) was associated to lower bone mass acquisition in adolescents during the study period.

Trial registration: (Register Number):RBR-5 h9b3c.

Extreme Preterm Birth

PS-043 PERINATAL FACTORS ASSOCIATED WITH SURVIVAL IN INFANTS AT THE LIMIT OF VIABILITY

¹F García-Muñoz Rodrigo, ²A García-Alix Pérez, ³JA García Hernández, ²JA Figueras Aloy. ¹Neonatology, Spanish SEN1500 Network, Las Palmas de Gran Canaria, Spain; ²Neonatology, Spanish SEN1500 Network, Barcelona, Spain; ³Obstetrics, Complejo Hospitalario Universitario Insular- Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain

10.1136/archdischild-2014-307384.340

Background and aims Decisions in pregnancies at the limit of viability are usually taken primarily based on gestational age. Other factors, however, may be critical to the results. The aim of our study was to know which perinatal factors are associated with survival in neonates ≤ 26 weeks GA.

Methods Retrospective analysis of prospectively collected data. We included all inborn infants ≤ 26 weeks GA without major congenital malformations, admitted to the NICUs participating in the Spanish SEN1500 network, during the period 2004–2010. The relation of risk factors to the likelihood of survival was analysed with the Cox Proportional-Hazards Regression method.

Results During the study period 3,915 infants ≤ 26 weeks GA were born alive. Of these, 3,518 (89.9%) were “inborns”. Infants who died in the delivery room and/or who had severe congenital malformations were excluded. Finally, 3,236 patients were included. After correcting for potential confounders, survival was related to the following antenatal and postnatal variables:

Conclusions GA, birth weight, female sex, antenatal steroid and single gestation are factors potentially known prenatally that are associate with a higher probability of survival. After birth, in the first 12 h after admission, the CRIB I score and the temperature

Abstract PS-043 Table 1

Variables	OR	95% CI	p
Gestational age	1.665	1,507–1,839	< 0.001
Birth weight	1.003	1,003–1,004	< 0.001
Antenatal steroids	2.805	2,270–3,467	< 0.001
Sex (male)	0.716	0,610–0,840	< 0.001
Multiple gestation	0.697	0,588–0,826	< 0.001
Admission temperature	1.397	1.222–1.597	< 0.001
CRIB score I	0.845	0.815–0.876	< 0.001